peptide,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM,netmhcpan_ba_BAV,ann_BAV,smmpmbec_BAV,smm_BAV,mhcflurry_BAV,netmhcpan_ba_BAV_Normalized,ann_BAV_Normalized,smmpmbec_BAV_Normalized,smm_BAV_Normalized,mhcflurry_BAV_Normalized,VTAPERNet_BAV_Normalized,VTAPERNet_BAV
CWNVEQARF,Positive-High,,1925.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3010317727472659,279.97,368.75,851.0596491020302,572.3082415101953,116.75,0.4792238522400543,0.4537670964875827,0.3764676094343331,0.4131416039141832,0.5600616970675342,0.46341240406036377,332.20718259125493
RVAVILNEF,Positive-High,,2530.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2757730911166582,967.57,1569.41,907.7369206678108,854.338543482408,470.11,0.3646091820926266,0.3199070407812896,0.3705088567770138,0.3761122124008428,0.4313222925520448,0.2940742075443268,2075.5066252637703
KYISTSLPV,Positive-High,,7135.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1799492284703009,131.44,240.27,454.9461561308376,453.55504284176845,94.6,0.5491080920984962,0.4933571514212894,0.4343526352482901,0.4346356759995128,0.57950548001402,0.4066814184188843,613.7425280195968
IWEQLASRF,Positive-High,,6405.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1899247855235927,401.23,94.75,434.4702061439005,433.1417032665245,100.92,0.4459650954583378,0.5793590474473762,0.4386088871463752,0.4388919278975977,0.5735284030337822,0.46302348375320435,333.60806629224004
FFNKGGSVF,Positive-Intermediate,,13260.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1226708150372021,290.57,598.67,1009.1599347312964,1317.1341194590916,77.94,0.4757892110143736,0.4089795224989863,0.3607194774114183,0.3361034445588433,0.5974095600288931,0.2758610248565674,2527.5940430926194
LMKGGANLF,Positive-Intermediate,,26720.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0579134470493315,1258.68,821.12,1018.4975766405184,989.988158677964,232.21,0.3402989743287008,0.3797775623871785,0.3598682270318014,0.3624922063269707,0.4965107425068169,0.2376238852739334,3822.8080786329697
LFTKLHPAF,Positive-Intermediate,,19600.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0865538474610913,234.04,490.66,809.0213821238207,854.3385434824045,41.58,0.4957852279856233,0.4273679865973726,0.3811494865222268,0.3761122124008431,0.655480991897882,0.45120686292648315,379.1075989912768
SYYMPQLFW,Positive-Intermediate,,27770.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0543510863763961,41.79,67.36,205.09732685070875,156.9025493305815,71.34,0.6550153821693336,0.6108930091478733,0.5079857930851619,0.5327422822503738,0.6055873727024955,0.5728241205215454,101.69196615466451
EMQSLHFAF,Positive-High,,4845.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2157230673985694,365.9,435.21,628.0005151645744,515.9765923596126,297.74,0.4544841939571351,0.4384516472048877,0.4045588719616948,0.4227181706848744,0.4735362894952911,0.395486056804657,692.7760835434979
KYSDVIKVL,Positive-High,,1376.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3320624666675245,247.58,439.64,837.4521463815693,969.6834870982608,37.29,0.4905871805113359,0.4375156264551491,0.377957297598663,0.3644075196811093,0.6655453467651198,0.4413830637931824,421.6229350091387
DYPGQGFSF,Positive-High,,5841.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.198444083966458,305.51,100.14,54.32002985919668,55.0338632056369,59.94,0.4711552897951069,0.5742455080120088,0.6307786603449161,0.6295720129318088,0.6216794878517587,0.508090615272522,204.86484699651058
RFTLSVPGF,Positive-High,,1597.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3182963685270169,294.69,636.33,610.8857576568441,596.5268551115099,50.46,0.4744879417217382,0.4033410734487065,0.4071126231005457,0.4093109772059063,0.6375913775550504,0.3573301434516907,1046.8546310602471
VYSFLCKTI,Positive-High,,606.9,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.4077176200481553,30.2,55.0,188.78174666745525,152.27548801155638,44.08,0.6850358819929772,0.6296288999741841,0.5156470465017149,0.5355088459841291,0.6500846814671111,0.6677803993225098,36.39904074243972
QYDPVAALF,Positive-High,,707.4,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.393555384935597,66.55,104.98,138.02571323684202,127.53518015983992,31.89,0.6120111304970308,0.5698830665939287,0.5445895594086934,0.5518954157917564,0.6800033799203979,0.5293537378311157,162.76186913359624
HYSPLILAL,Positive,,64.0,nM,HLA-A*24:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.6156221528723917,190.48,314.8,601.1183698856396,637.7199450443057,35.02,0.5148193369412721,0.4683867482912336,0.4086023112648754,0.4031394119536833,0.6713500745222049,0.5969244241714478,78.35018753282279
